We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+31.78%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$232M
AUM Growth
+$30.7M
Cap. Flow
-$28.5M
Cap. Flow %
-12.3%
Top 10 Hldgs %
46.06%
Holding
89
New
6
Increased
22
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$5.79M
2
SAGE
Sage Therapeutics
SAGE
+$2.82M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$2.27M
4
MRSN
Mersana Therapeutics
MRSN
+$2.03M
5
BPMC
Blueprint Medicines
BPMC
+$2M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$25.4M
2
NXTM
NxStage Medical Inc.
NXTM
+$8.93M
3
ASND icon
Ascendis Pharma A/S
ASND
+$2.88M
4
ARGX icon
argenx
ARGX
+$2.66M
5
KURA icon
Kura Oncology
KURA
+$1.73M

Sector Composition

Rank Sector Weight
1 Healthcare 88.92%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRMR icon
51
Larimar Therapeutics
LRMR
$413M
$910K 0.39%
27,667
+21,644
+359% +$1.11M
MGNX icon
52
MacroGenics
MGNX
$243M
$899K 0.39%
50,000
-28,305
-36% -$489K
SPRO icon
53
Spero Therapeutics
SPRO
$66.6M
$897K 0.39%
70,000
– –
ABUS icon
54
Arbutus Biopharma
ABUS
$861M
$884K 0.38%
246,900
– –
RDUS
55
DELISTED
Radius Health, Inc.
RDUS
$837K 0.36%
42,000
+21,500
+105% +$392K
MDGL icon
56
Madrigal Pharmaceuticals
MDGL
$11.1B
$827K 0.36%
6,600
– –
SVRA icon
57
Savara
SVRA
$1.09B
$813K 0.35%
+110,275
New +$831K
PHAS
58
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$689K 0.3%
72,500
-27,500
-28% -$109K
KALV
59
DELISTED
KalVista Pharmaceuticals
KALV
$665K 0.29%
23,225
+3,000
+15% +$65K
KURA icon
60
Kura Oncology
KURA
$816M
$606K 0.26%
36,558
-112,059
-75% -$1.73M
CDTX
61
DELISTED
Cidara Therapeutics
CDTX
$564K 0.24%
10,638
– –
OBSV
62
DELISTED
ObsEva SA Ordinary Shares
OBSV
$555K 0.24%
43,408
-930
-2% -$12K
URGN icon
63
UroGen Pharma
URGN
$1.88B
$554K 0.24%
15,000
– –
ALDX icon
64
Aldeyra Therapeutics
ALDX
$92.3M
$452K 0.2%
50,000
– –
MASI
65
DELISTED
Masimo
MASI
$415K 0.18%
3,000
– –
STRO icon
66
Sutro Biopharma
STRO
$416M
$359K 0.15%
3,149
– –
RIGL icon
67
Rigel Pharmaceuticals
RIGL
$693M
$354K 0.15%
13,760
– –
ARCT icon
68
Arcturus Therapeutics
ARCT
$171M
$323K 0.14%
47,255
-25,550
-35% -$131K
NERV icon
69
Minerva Neurosciences
NERV
$185M
$284K 0.12%
4,511
+1,250
+38% +$75.1K
SLGL icon
70
Sol-Gel Technologies
SLGL
$268M
$237K 0.1%
3,500
– –
RNTX
71
Rein Therapeutics
RNTX
$63.8M
$194K 0.08%
+4,975
New +$155K
LCTX icon
72
Lineage Cell Therapeutics
LCTX
$277M
$124K 0.05%
95,000
-5,000
-5% -$6.22K
BLCM
73
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$101K 0.04%
3,000
– –
IMMU
74
DELISTED
Immunomedics Inc
IMMU
$97K 0.04%
5,052
-77,202
-94% -$1.24M
ORMP icon
75
Oramed Pharmaceuticals
ORMP
$180M
$95K 0.04%
26,000
+10,000
+63% +$33.1K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, DAFNA Capital Management held 89 positions worth $232M, up 15% from $201M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

DAFNA Capital Management withdrew a net $28.5M in Q1 2019, closing 10 positions and reducing 19 holdings. Its most notable exit was Loxo Oncology, Inc, an estimated $25.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 89% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in Mersana Therapeutics worth $2.12M.

  • DAFNA Capital Management's largest Q1 2019 buy was Mersana Therapeutics: 16,132 shares worth $2.12M.
  • DAFNA Capital Management added most to Wave Life Sciences in Q1 2019, an estimated $5.79M increase.
  • DAFNA Capital Management's biggest Q1 2019 reduction was Ascendis Pharma A/S, cutting an estimated $2.88M.
  • DAFNA Capital Management fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $25.4M.
  • DAFNA Capital Management's ten largest holdings make up 46% of its $232M portfolio in Q1 2019.
  • DAFNA Capital Management opened 6 new positions and closed 10 in Q1 2019.
  • DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $232M.

Based on DAFNA Capital Management's 13F filing for Q1 2019, filed 15 May 2019.